Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: A randomized, double-blind, placebo-controlled extension trial

JD Adachi; KG Saag; PD Delmas; UA Liberman; RD Emkey; E Seeman; NE Lane; JM Kaufman; PEE Poubelle; F Hawkins; R Correa-Rotter; CJ Menkes; JA Rodriguez-Portales; TJ Schnitzer; JA Block; J Wing; HH McIlwain; R Westhovens; J Brown; JA Melo-Gomes; BL Gruber; MJ Yanover; MOR Leite; KG Siminoski; MC Nevitt; JT Sharp; MP Malice; T Dumortier; M Czachur; W Carofano; A Daifotis

Journal article

Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: A randomized, double-blind, placebo-controlled extension trial

JD Adachi, KG Saag, PD Delmas, UA Liberman, RD Emkey, E Seeman, NE Lane, JM Kaufman, PEE Poubelle, F Hawkins, R Correa-Rotter, CJ Menkes, JA Rodriguez-Portales, TJ Schnitzer, JA Block, J Wing, HH McIlwain, R Westhovens, J Brown, JA Melo-Gomes Show all

Arthritis and Rheumatism | Published : 2001

DOI: 10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W

Abstract

Objective. To evaluate the continued efficacy and safety of alendronate (ALN) for up to 2 years in patients receiving glucocorticoids. Methods. This is a 12-month extension of a previously completed 1-year trial of daily ALN, performed to evaluate the effects of ALN over a total of 2 years in 66 men and 142 women continuing to receive at least 7.5 mg of prednisone or equivalent daily. All patients received supplemental calcium and vitamin D. The primary end point was the mean percentage change in lumbar spine bone mineral density (BMD) from baseline to 24 months. Other outcomes included changes in hip and total body BMD, biochemical markers of bone turnover, radiographic joint damage of the ..

View full abstract